Dan Kemp

Dan Kemp is currently the Chief Executive Officer at Shinobi Therapeutics, a position Dan took up in March 2023. Prior to this role, Kemp served as the CEO at Wugen, where Dan focused on developing cell therapies for cancer treatment. Dan also held positions as a Board Director at Adaptate Biotherapeutics and GammaDelta Therapeutics before both companies were acquired by Takeda. Kemp's extensive experience in the pharmaceutical industry includes roles at Takeda, Beryllium, Merck Research Laboratories, Novartis, and Pfizer. Dan holds a PhD in Molecular Pharmacology from the University of Kent and completed their post-doctoral research at Harvard Medical School.